FoxM1 Is a General Target for Proteasome Inhibitors
Proteasome inhibitors are currently in the clinic or in clinical trials, but the mechanism of their anticancer activity is not completely understood. The oncogenic transcription factor FoxM1 is one of the most overexpressed genes in human tumors, while its expression is usually halted in normal non-...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Public Library of Science
2009
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721658/ |